33.92 +0.80 (2.42%)
After hours: 7:32PM EST
Previous Close | 31.57 |
Open | 31.21 |
Bid | 32.83 x 800 |
Ask | 33.55 x 900 |
Day's Range | 30.71 - 33.54 |
52 Week Range | 2.94 - 60.00 |
Volume | 110,257 |
Avg. Volume | 1,819,877 |
Market Cap | 145.025M |
Beta (5Y Monthly) | 7.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.84 |
Earnings Date | Nov 10, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 65.67 |
SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRâ„¢ and ADAPTIR-FLEXâ„¢ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial.
Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
PHILADELPHIA, PA / ACCESSWIRE / December 19, 2020 / Kaskela Law LLC announces that it is investigating Aptevo Therapeutics Inc.